About

Add to Google Reader or Homepage

Subscribe in NewsGator Online

Subscribe in Bloglines

« Retinal Disease: Much Progress, Some Pain | Main | Changing Form, But Not Function: Smith & Nephew Expands NPWT Market »

April 02, 2012

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d83452f00669e20163039ad03d970d

Listed below are links to weblogs that reference FDA’s Final Risk-Benefit Guidance Excludes 510(k)s, Adds De Novo Petitions:

Comments

The comments to this entry are closed.